These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26857424)

  • 1. Evaluation of Quality of Life, Functioning, Disability, and Work/School Productivity Following Treatment with an Extended-Release Hydrocodone Tablet Formulated with Abuse-Deterrence Technology: A 12-month Open-label Study in Patients with Chronic Pain.
    Hale ME; Zimmerman TR; Ma Y; Malamut R
    Pain Pract; 2017 Feb; 17(2):229-238. PubMed ID: 26857424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potential.
    Hale ME; Ma Y; Malamut R
    J Opioid Manag; 2016; 12(2):139-47. PubMed ID: 27194199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twelve-month, open-label assessment of long-term safety and abuse potential of hydrocodone extended-release formulated with abuse-deterrence technology in patients with chronic pain.
    Hale ME; Zimmerman TR; Ma Y; Malamut R
    J Opioid Manag; 2015; 11(5):425-34. PubMed ID: 26535970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain.
    Hale ME; Zimmerman TR; Eyal E; Malamut R
    J Opioid Manag; 2015; 11(6):507-18. PubMed ID: 26728648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain.
    Taber L; Lynch SY; He E; Ripa SR
    Postgrad Med; 2016 Jan; 128(1):23-33. PubMed ID: 26681111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability of Biphasic-Release Hydrocodone Bitartrate/Acetaminophen Tablets (MNK-155): A Phase III, Multicenter, Open-Label Study in Patients With Osteoarthritis or Chronic Low Back Pain.
    Zheng Y; Kostenbader K; Barrett T; Hisaw E; Giuliani MJ; Chen Y; Young JL
    Clin Ther; 2015 Jun; 37(6):1235-47. PubMed ID: 25913923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Once-Daily Extended-Release (ER) Hydrocodone in Individuals Previously Receiving ER Morphine for Chronic Pain.
    Broglio K; Pergolizzi J; Kowalski M; Lynch SY; He E; Wen W
    Pain Pract; 2017 Mar; 17(3):382-391. PubMed ID: 27317188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pain intensity and interference with functioning and well-being in subgroups of patients with chronic pain treated with once-daily hydrocodone tablets.
    Bartoli A; Michna E; He E; Wen W
    J Opioid Manag; 2015; 11(6):519-33. PubMed ID: 26728649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain.
    Bartoli A; Michna E; He E; Wen W
    Postgrad Med; 2015 Jan; 127(1):5-12. PubMed ID: 25526227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind, placebo-controlled study of the efficacy and safety of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen tablets for acute postoperative pain.
    Singla N; Margulis R; Kostenbader K; Zheng Y; Barrett T; Giuliani MJ; Chen Y; Young JL
    Phys Sportsmed; 2015 May; 43(2):126-37. PubMed ID: 25796986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 12-Month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic pain.
    Wen W; Taber L; Lynch SY; He E; Ripa S
    J Opioid Manag; 2015; 11(4):339-56. PubMed ID: 26312961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hysingla® ER, a once-daily, single-entity hydrocodone with abuse-deterrent properties in treating chronic nonmalignant and nonneuropathic pain in patients with osteoarthritis.
    Taber L; Baldridge S; He E; Ripa SR
    Postgrad Med; 2017 Jan; 129(1):133-139. PubMed ID: 27983881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects.
    Darwish M; Bond M; Tracewell W; Robertson P; Yang R
    Clin Drug Investig; 2015 Jan; 35(1):13-22. PubMed ID: 25391549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
    Darwish M; Yang R; Tracewell W; Robertson P; Bond M
    Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.
    Bond M; Schoedel KA; Rabinovich-Guilatt L; Gasior M; Tracewell W; Malamut R; Ma Y; Webster LR
    Pain Med; 2018 Aug; 19(8):1597-1612. PubMed ID: 29016880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology.
    Darwish M; Yang R; Tracewell W; Robertson P; Bond M
    Clin Pharmacol Drug Dev; 2016 Mar; 5(2):141-9. PubMed ID: 27138027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between change in pain intensity and functional outcomes in patients with chronic pain receiving twice daily extended-release hydrocodone bitartrate.
    Argoff C; Arnstein P; Stanos S; Robinson CY; Galer BS; Gould E; Gammaitoni A
    J Opioid Manag; 2015; 11(5):417-24. PubMed ID: 26535969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study.
    Rauck RL; Nalamachu S; Wild JE; Walker GS; Robinson CY; Davis CS; Farr SJ
    Pain Med; 2014 Jun; 15(6):975-85. PubMed ID: 24517082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.
    Darwish M; Bond M; Ma Y; Tracewell W; Robertson P; Webster LR
    Pain Med; 2017 Jan; 18(1):61-77. PubMed ID: 27330154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Alcohol-Induced Dose Dumping with a Hydrocodone Bitartrate Extended-Release Tablet Formulated with CIMA(®) Abuse Deterrence Technology.
    Darwish M; Bond M; Yang R; Tracewell W; Robertson P
    Clin Drug Investig; 2015 Oct; 35(10):645-52. PubMed ID: 26369654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.